EGFR mutation, smoking, and gender in advanced lung adenocarcinoma

Chien Hua Tseng, Chun Ju Chiang, Jeng Sen Tseng, Tsung Ying Yang, Kuo Hsuan Hsu, Kun Chieh Chen, Chih Liang Wang, Chih Yi Chen, Sang Hue Yen, Chun Ming Tsai, Ming Shyan Huang, Chao Chi Ho, Chong Jen Yu, Ying Huang Tsai, Jin Shing Chen, Teh Ying Chou, Ming Hsun Tsai, Hsuan Yu Chen, Kang Yi Su, Jeremy J.W. ChenHuei Wen Chen, Sung Liang Yu, Tsang Wu Liu, Gee Chen Chang

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: In the current targeted therapy era, information on the effect of smoking in epidermal growth factor receptor (EGFR)-mutant lung cancer patients is scarce. Results: In total, 11,678 adenocarcinoma patients were enrolled. Of these, 33.3% and 91.8% of male and female patients were non-smokers, respectively. An increased amount of smoking (P < 0.001 for trend), fewer smoke-free years (P < 0.001 for trend), and younger age of smoking initiation (P = 0.034 for trend) were all associated with significantly lower EGFR mutation rates. Smokers had a shorter median overall survival (OS) among both EGFR-mutant and EGFR-wild type patients (17.8 vs. 21.1 months, and 7.9 vs. 11.4 months respectively; both P < 0.001). Among patients with EGFR-mutant adenocarcinoma, younger smokers were associated with shorter OS (P = 0.047). In multivariate analysis, female gender was an independent prognostic factor for OS (hazard ratio: 0.86 [95% confidence interval (CI): 0.80-0.93]; P < 0.001 in the EGFRmutant group and 0.88 [95% CI: 0.81-0.96]; P = 0.004 in the EGFR-wild type group). Materials and Methods: We reviewed the National Lung Cancer database (Taiwan) to assess the impact of smoking on the EGFR mutation rate and survival in advanced lung adenocarcinoma patients during 2011 and 2014 retrospectively. Conclusions: Smoking was associated with lower incidence of EGFR mutation rate and reduced OS of advanced lung adenocarcinoma patients in a dose-dependent manner. In addition to EGFR mutation and smoking, gender also plays an important role in survival among these patients.

Original languageEnglish
Pages (from-to)98384-98393
Number of pages10
JournalOncotarget
Volume8
Issue number58
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Epidermal Growth Factor Receptor
Smoking
Mutation
Survival
Mutation Rate
Lung Neoplasms
Adenocarcinoma
Confidence Intervals
Adenocarcinoma of lung
Taiwan
Smoke
Multivariate Analysis
Databases
Incidence

Keywords

  • Epidermal growth factor receptor (EGFR) mutation
  • Lung adenocarcinoma
  • Overall survival
  • Smoking

ASJC Scopus subject areas

  • Oncology

Cite this

Tseng, C. H., Chiang, C. J., Tseng, J. S., Yang, T. Y., Hsu, K. H., Chen, K. C., ... Chang, G. C. (2017). EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget, 8(58), 98384-98393. https://doi.org/10.18632/oncotarget.21842

EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. / Tseng, Chien Hua; Chiang, Chun Ju; Tseng, Jeng Sen; Yang, Tsung Ying; Hsu, Kuo Hsuan; Chen, Kun Chieh; Wang, Chih Liang; Chen, Chih Yi; Yen, Sang Hue; Tsai, Chun Ming; Huang, Ming Shyan; Ho, Chao Chi; Yu, Chong Jen; Tsai, Ying Huang; Chen, Jin Shing; Chou, Teh Ying; Tsai, Ming Hsun; Chen, Hsuan Yu; Su, Kang Yi; Chen, Jeremy J.W.; Chen, Huei Wen; Yu, Sung Liang; Liu, Tsang Wu; Chang, Gee Chen.

In: Oncotarget, Vol. 8, No. 58, 01.01.2017, p. 98384-98393.

Research output: Contribution to journalArticle

Tseng, CH, Chiang, CJ, Tseng, JS, Yang, TY, Hsu, KH, Chen, KC, Wang, CL, Chen, CY, Yen, SH, Tsai, CM, Huang, MS, Ho, CC, Yu, CJ, Tsai, YH, Chen, JS, Chou, TY, Tsai, MH, Chen, HY, Su, KY, Chen, JJW, Chen, HW, Yu, SL, Liu, TW & Chang, GC 2017, 'EGFR mutation, smoking, and gender in advanced lung adenocarcinoma', Oncotarget, vol. 8, no. 58, pp. 98384-98393. https://doi.org/10.18632/oncotarget.21842
Tseng CH, Chiang CJ, Tseng JS, Yang TY, Hsu KH, Chen KC et al. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget. 2017 Jan 1;8(58):98384-98393. https://doi.org/10.18632/oncotarget.21842
Tseng, Chien Hua ; Chiang, Chun Ju ; Tseng, Jeng Sen ; Yang, Tsung Ying ; Hsu, Kuo Hsuan ; Chen, Kun Chieh ; Wang, Chih Liang ; Chen, Chih Yi ; Yen, Sang Hue ; Tsai, Chun Ming ; Huang, Ming Shyan ; Ho, Chao Chi ; Yu, Chong Jen ; Tsai, Ying Huang ; Chen, Jin Shing ; Chou, Teh Ying ; Tsai, Ming Hsun ; Chen, Hsuan Yu ; Su, Kang Yi ; Chen, Jeremy J.W. ; Chen, Huei Wen ; Yu, Sung Liang ; Liu, Tsang Wu ; Chang, Gee Chen. / EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. In: Oncotarget. 2017 ; Vol. 8, No. 58. pp. 98384-98393.
@article{da5d96c6c0f1466e90ef5d7c78dd4c55,
title = "EGFR mutation, smoking, and gender in advanced lung adenocarcinoma",
abstract = "Purpose: In the current targeted therapy era, information on the effect of smoking in epidermal growth factor receptor (EGFR)-mutant lung cancer patients is scarce. Results: In total, 11,678 adenocarcinoma patients were enrolled. Of these, 33.3{\%} and 91.8{\%} of male and female patients were non-smokers, respectively. An increased amount of smoking (P < 0.001 for trend), fewer smoke-free years (P < 0.001 for trend), and younger age of smoking initiation (P = 0.034 for trend) were all associated with significantly lower EGFR mutation rates. Smokers had a shorter median overall survival (OS) among both EGFR-mutant and EGFR-wild type patients (17.8 vs. 21.1 months, and 7.9 vs. 11.4 months respectively; both P < 0.001). Among patients with EGFR-mutant adenocarcinoma, younger smokers were associated with shorter OS (P = 0.047). In multivariate analysis, female gender was an independent prognostic factor for OS (hazard ratio: 0.86 [95{\%} confidence interval (CI): 0.80-0.93]; P < 0.001 in the EGFRmutant group and 0.88 [95{\%} CI: 0.81-0.96]; P = 0.004 in the EGFR-wild type group). Materials and Methods: We reviewed the National Lung Cancer database (Taiwan) to assess the impact of smoking on the EGFR mutation rate and survival in advanced lung adenocarcinoma patients during 2011 and 2014 retrospectively. Conclusions: Smoking was associated with lower incidence of EGFR mutation rate and reduced OS of advanced lung adenocarcinoma patients in a dose-dependent manner. In addition to EGFR mutation and smoking, gender also plays an important role in survival among these patients.",
keywords = "Epidermal growth factor receptor (EGFR) mutation, Lung adenocarcinoma, Overall survival, Smoking",
author = "Tseng, {Chien Hua} and Chiang, {Chun Ju} and Tseng, {Jeng Sen} and Yang, {Tsung Ying} and Hsu, {Kuo Hsuan} and Chen, {Kun Chieh} and Wang, {Chih Liang} and Chen, {Chih Yi} and Yen, {Sang Hue} and Tsai, {Chun Ming} and Huang, {Ming Shyan} and Ho, {Chao Chi} and Yu, {Chong Jen} and Tsai, {Ying Huang} and Chen, {Jin Shing} and Chou, {Teh Ying} and Tsai, {Ming Hsun} and Chen, {Hsuan Yu} and Su, {Kang Yi} and Chen, {Jeremy J.W.} and Chen, {Huei Wen} and Yu, {Sung Liang} and Liu, {Tsang Wu} and Chang, {Gee Chen}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.21842",
language = "English",
volume = "8",
pages = "98384--98393",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "58",

}

TY - JOUR

T1 - EGFR mutation, smoking, and gender in advanced lung adenocarcinoma

AU - Tseng, Chien Hua

AU - Chiang, Chun Ju

AU - Tseng, Jeng Sen

AU - Yang, Tsung Ying

AU - Hsu, Kuo Hsuan

AU - Chen, Kun Chieh

AU - Wang, Chih Liang

AU - Chen, Chih Yi

AU - Yen, Sang Hue

AU - Tsai, Chun Ming

AU - Huang, Ming Shyan

AU - Ho, Chao Chi

AU - Yu, Chong Jen

AU - Tsai, Ying Huang

AU - Chen, Jin Shing

AU - Chou, Teh Ying

AU - Tsai, Ming Hsun

AU - Chen, Hsuan Yu

AU - Su, Kang Yi

AU - Chen, Jeremy J.W.

AU - Chen, Huei Wen

AU - Yu, Sung Liang

AU - Liu, Tsang Wu

AU - Chang, Gee Chen

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose: In the current targeted therapy era, information on the effect of smoking in epidermal growth factor receptor (EGFR)-mutant lung cancer patients is scarce. Results: In total, 11,678 adenocarcinoma patients were enrolled. Of these, 33.3% and 91.8% of male and female patients were non-smokers, respectively. An increased amount of smoking (P < 0.001 for trend), fewer smoke-free years (P < 0.001 for trend), and younger age of smoking initiation (P = 0.034 for trend) were all associated with significantly lower EGFR mutation rates. Smokers had a shorter median overall survival (OS) among both EGFR-mutant and EGFR-wild type patients (17.8 vs. 21.1 months, and 7.9 vs. 11.4 months respectively; both P < 0.001). Among patients with EGFR-mutant adenocarcinoma, younger smokers were associated with shorter OS (P = 0.047). In multivariate analysis, female gender was an independent prognostic factor for OS (hazard ratio: 0.86 [95% confidence interval (CI): 0.80-0.93]; P < 0.001 in the EGFRmutant group and 0.88 [95% CI: 0.81-0.96]; P = 0.004 in the EGFR-wild type group). Materials and Methods: We reviewed the National Lung Cancer database (Taiwan) to assess the impact of smoking on the EGFR mutation rate and survival in advanced lung adenocarcinoma patients during 2011 and 2014 retrospectively. Conclusions: Smoking was associated with lower incidence of EGFR mutation rate and reduced OS of advanced lung adenocarcinoma patients in a dose-dependent manner. In addition to EGFR mutation and smoking, gender also plays an important role in survival among these patients.

AB - Purpose: In the current targeted therapy era, information on the effect of smoking in epidermal growth factor receptor (EGFR)-mutant lung cancer patients is scarce. Results: In total, 11,678 adenocarcinoma patients were enrolled. Of these, 33.3% and 91.8% of male and female patients were non-smokers, respectively. An increased amount of smoking (P < 0.001 for trend), fewer smoke-free years (P < 0.001 for trend), and younger age of smoking initiation (P = 0.034 for trend) were all associated with significantly lower EGFR mutation rates. Smokers had a shorter median overall survival (OS) among both EGFR-mutant and EGFR-wild type patients (17.8 vs. 21.1 months, and 7.9 vs. 11.4 months respectively; both P < 0.001). Among patients with EGFR-mutant adenocarcinoma, younger smokers were associated with shorter OS (P = 0.047). In multivariate analysis, female gender was an independent prognostic factor for OS (hazard ratio: 0.86 [95% confidence interval (CI): 0.80-0.93]; P < 0.001 in the EGFRmutant group and 0.88 [95% CI: 0.81-0.96]; P = 0.004 in the EGFR-wild type group). Materials and Methods: We reviewed the National Lung Cancer database (Taiwan) to assess the impact of smoking on the EGFR mutation rate and survival in advanced lung adenocarcinoma patients during 2011 and 2014 retrospectively. Conclusions: Smoking was associated with lower incidence of EGFR mutation rate and reduced OS of advanced lung adenocarcinoma patients in a dose-dependent manner. In addition to EGFR mutation and smoking, gender also plays an important role in survival among these patients.

KW - Epidermal growth factor receptor (EGFR) mutation

KW - Lung adenocarcinoma

KW - Overall survival

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=85035042768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035042768&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21842

DO - 10.18632/oncotarget.21842

M3 - Article

AN - SCOPUS:85035042768

VL - 8

SP - 98384

EP - 98393

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 58

ER -